{"Understate": "The claim understates the complexity and lengthiness of the process involved in vaccine production, including factors such as supplies, ingredients, storage capacity, training, and facility compliance.", "Lack enough support": "The claim lacks enough support for the assertion that \"dozens\" of other pharmaceutical companies are ready to produce the vaccines.", "Problematic assumption": "The claim assumes that sharing the vaccine design with other pharmaceutical companies would immediately lead to the end of the pandemic, without considering the time and investment required for production and distribution.", "Exist alternative explanation": "The claim does not mention that Pfizer and Moderna already have partnerships with various contract manufacturers to speed up vaccine production, suggesting an alternative explanation for their approach.", "Contradict fact": "The claim contradicts the fact that the mRNA technology used in Pfizer and Moderna's vaccines is fragile and requires specific handling conditions, which may limit immediate production capabilities of other companies.", "Exaggerate": "The claim exaggerates the readiness and capability of other pharmaceutical companies to produce the vaccines, implying that they have a ready supply of raw materials, equipment, and storage, which experts say is not the case."}